Palvella Therapeutics (PVLA) Operating Income (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Operating Income for 14 consecutive years, with -$14.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Income fell 88.73% year-over-year to -$14.9 million; the TTM figure through Mar 2026 stood at -$45.6 million (down 125.6% YoY), while the FY2025 annual figure was -$38.6 million, down 173.87% from the prior year.
• Operating Income slipped to -$14.9 million in Q1 2026 per PVLA's latest filing, from -$11.3 million in the prior quarter.
• Across five years, Operating Income topped out at $13.4 million in Q4 2023 and bottomed at -$15.5 million in Q1 2023.
• Historically, Operating Income has averaged -$7.2 million across 5 years, with a median of -$9.2 million in 2025.
• Annual changes were most pronounced in 2023 — Operating Income soared 216.21% — and 2025, when it plunged 347.47%.
• Palvella Therapeutics' Operating Income stood at -$11.5 million in 2022, then jumped by 216.21% to $13.4 million in 2023, then tumbled by 132.62% to -$4.4 million in 2024, then sank by 158.91% to -$11.3 million in 2025, then sank by 31.41% to -$14.9 million in 2026.
• Business Quant data shows PVLA's Operating Income at -$14.9 million in Q1 2026, -$11.3 million in Q4 2025, and -$10.2 million in Q3 2025.